Literature DB >> 7590880

CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.

M Kryworuckho1, F Diaz-Mitoma, A Kumar.   

Abstract

CD44, a cell adhesion molecule, exists in multiple isoforms that are generated by RNA alternative splicing. CD44 isoforms containing exon V6 (CD44 V6) have been associated with tumorigenesis and metastasis. We investigated the association between human B-cell activation and CD44 V6 isoform expression by analysing its expression in resting and mitogenically stimulated B cells. Results showed that resting B cells expressed the CD44 H (no variable exon) isoform alone. Activation of B cells [phorbol myristate acetate (PMA), surface immunoglobulin cross-linking alone or in the presence of interleukin-2 (IL-2)] induced CD44E (variable exon V8-10), R2 (VIO) and CD44 isoforms containing exons V6 and/or V7 (CD44 V6/V7). Epstein-Barr virus (EBV) infection of B cells, an alternative method of B-cell activation, induced the expression of CD44 E and R2 but not CD44 V6/V7. These results indicate that CD44 V6/V7 expression depends on the mode of activation. CD44 isoform expression was also investigated in a panel of EBV-negative and EBV-positive Burkitt's lymphoma (BL) B-cell lines. EBV-negative BL cells did not express CD44. In contrast, EBV-positive BL cells expressed CD44 H, R2 and E but not CD44 V6/V7 isoforms, suggesting an association between EBV infection and CD44 isoform induction. To determine directly the role of EBV in CD44 isoform induction, an EBV-negative BL cell line, BL30 (negative for all isoforms of CD44), BL30 infected in vitro with the EBNA-2-defective P3HR1 (BL30/P3HR1), and the wild-type B95-8 strain of EBV (BL30/B95-8) were examined. The parental BL30 cells infected with the wild-type EBV strain, but not with the P3HR-1 strain, expressed CD44 H, R2 and E isoforms, as seen in EBV-immortalized B cells. These studies suggest that (1) alternative splicing of CD44 isoforms is differentially regulated depending on the mode and state of cell activation, and that (2) the CD44 V6/V7 isoforms may represent B-cell activation antigens that are induced by mitogenic stimulation but not following EBV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590880      PMCID: PMC1383808     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.

Authors:  A Calender; M Billaud; J P Aubry; J Banchereau; M Vuillaume; G M Lenoir
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.

Authors:  B Ehlin-Henriksson; A Manneborg-Sandlund; G Klein
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

Review 3.  Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma.

Authors:  K Nilsson; G Klein
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

4.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.

Authors:  F Wang; C D Gregory; M Rowe; A B Rickinson; D Wang; M Birkenbach; H Kikutani; T Kishimoto; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBV-transformed human B cells.

Authors:  A Kumar; T Rogers; A Maizel; S Sharma
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

6.  Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma.

Authors:  S Jalkanen; H Joensuu; K O Söderström; P Klemi
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

7.  High levels of CD44 expression distinguish virgin from antigen-primed B cells.

Authors:  R L Camp; T A Kraus; M L Birkeland; E Puré
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

8.  Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells.

Authors:  G J Dougherty; P M Landorp; D L Cooper; R K Humphries
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

9.  Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development.

Authors:  A Bartolazzi; R Peach; A Aruffo; I Stamenkovic
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  Distinct effects of two CD44 isoforms on tumor growth in vivo.

Authors:  M S Sy; Y J Guo; I Stamenkovic
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  6 in total

1.  Role of CD44 and its v7 isoform in staphylococcal enterotoxin B-induced toxic shock: CD44 deficiency on hepatic mononuclear cells leads to reduced activation-induced apoptosis that results in increased liver damage.

Authors:  Robert J McKallip; Michael Fisher; Ursula Gunthert; Andras K Szakal; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  CD44 and hyaluronan-dependent rolling interactions of lymphocytes on tonsillar stroma.

Authors:  R A Clark; R Alon; T A Springer
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

3.  Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients.

Authors:  D Masson; M G Denis; P Lustenberger
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

4.  T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans.

Authors:  Franklin R Toapanta; Paula J Bernal; Karen L Kotloff; Myron M Levine; Marcelo B Sztein
Journal:  J Transl Med       Date:  2018-03-13       Impact factor: 5.531

5.  Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity.

Authors:  John B Harley; Xiaoting Chen; Mario Pujato; Daniel Miller; Avery Maddox; Carmy Forney; Albert F Magnusen; Arthur Lynch; Kashish Chetal; Masashi Yukawa; Artem Barski; Nathan Salomonis; Kenneth M Kaufman; Leah C Kottyan; Matthew T Weirauch
Journal:  Nat Genet       Date:  2018-04-16       Impact factor: 38.330

6.  Early events associated with infection of Epstein-Barr virus infection of primary B-cells.

Authors:  Sabyasachi Halder; Masanao Murakami; Subhash C Verma; Pankaj Kumar; Fuming Yi; Erle S Robertson
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.